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Autologous stem cell transplantation (ASCT) is challenged by side effects that may be propagated by chemother-
apy-induced mucositis, resulting in bacterial translocation and systemic inflammation. Because gastrointestinal
damage appears as an early event in this cascade of reactions, we hypothesized that markers reflecting damage to
the intestinal barrier could serve as early predictive markers of toxicity. Glucagon-like peptide-1 (GLP-1), a well-
known regulator of blood glucose, has been found to promote intestinal growth and repair in animal studies. We
investigated fasting GLP-1 plasma levels in 66 adults undergoing ASCT for lymphoma and multiple myeloma.
GLP-1 increased significantly after chemotherapy, reaching peak levels at day +7 post-transplant (median, 8
pmol/L [interquartile range, 4 to 12] before conditioning versus 10 pmol/L [interquartile range, 6 to 17] at day +7;
P = .007). The magnitude of the GLP-1 increase was related to the intensity of conditioning. GLP-1 at the day of
transplantation (day 0) was positively associated with peak C-reactive protein (CRP) levels (46 mg/L per GLP-1
doubling, P < .001) and increase in days with fever (32% per GLP-1 doubling, P = .0058). Patients with GLP-1 above
the median at day 0 had higher CRP levels from days +3 to +10 post-transplant than patients with lower GLP-1
(P  .041) with peak values of 238 versus 129 mg/L, respectively. This study, which represents the first clinical
investigation of fasting GLP-1 in relation to high-dose chemotherapy, provides evidence that GLP-1 plays a role in
regulation of mucosal defenses. Fasting GLP-1 levels may serve as an early predictor of systemic inflammation
and fever in patients receiving high-dose chemotherapy.
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High-dose chemotherapy with autologous stem cell trans-
plantation (ASCT) is a potentially curative treatment of many
hematologic malignancies [1] but is challenged by severe side
effects and complications such as mucositis, organ toxicity,
and infections [2,3]. In most patients undergoing ASCT, varying
degrees of systemic inflammation are seen during the first
couple of weeks after conditioning with chemotherapy. This
inflammatory response is initiated because of chemotherapy-
induced injury to the mucosal barrier of the digestive tract[4-8], which increases intestinal permeability and translocation
of bacterial products into the bloodstream [5,7,9,10]. Many pre-
vious studies have suggested that this inflammatory response
plays a key role in induction of treatment-related complications
and results in poor prognosis [11-16].
C-reactive protein (CRP) is a reliable marker for systemic
inflammation after chemotherapy [17] and has been found to
reach maximum levels about 7 to 14 days after infusion of
stem cells [9,12,18,19]. This peak coincides with maximum
intensity of mucositis as measured by clinical scoring,
increased intestinal permeability, and a decline in citrulline, a
marker of functioning enterocytes [4,12,20]. Importantly, the
magnitude of the CRP response is associated with severe com-
plications such as mucositis, pneumonia, bacteremia, Clostrid-
ium difficile colitis, and other infections, with potentially fatal
outcome in patients undergoing ASCT [12,21]. However, the
Table 1
Patient Characteristics and Treatment Modalities (N = 66)
Characteristics Value
Median age, yr (range) 56 (20-72)
Sex
Male 41 (62)
Female 25 (38)
Diagnosis
Multiple myeloma 33 (50)
Non-Hodgkin lymphoma 29 (44)
Hodgkin lymphoma 3 (5)
Plasma cell leukemia 1 (2)
Conditioning regimen
Melphalan high dose +/- carfilzomib/bortezomib 33 (50)
BEAM 30 (45)
Ara-C + CP + VP16 + thiotepa + bortezomib + lenalidomide 1 (2)
BCNU + thiotepa + rituximab 2 (3)
Values are n (%) unless otherwise defined. Ara-C indicates cytarabine; BCNU,
carmustine; VP16, etoposide; CP, cyclophosphamide; BEAM, Ara-C + BCNU +
VP16 +melphalan.
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even among patients receiving the same conditioning regimen.
It is not well understood why some patients are more prone to
respond with severe inflammation than others, and we have at
present no biomarkers that with sufficient precision can pre-
dict the inflammatory response in individual patients, limiting
the possibility of personalized prophylaxis with antibiotics and
other early interventions.
Continued proliferation and regeneration of intestinal epithe-
lium is essential for maintenance of the mucosal barrier and
involves peptide hormones produced in the gut [22,23]. Gluca-
gon-like peptide- 1 (GLP-1) and GLP-2 are hormones co-secreted
from intestinal enteroendocrine L cells in response to food intake
and play a major role in regulating blood glucose through stimu-
lation of insulin secretion (GLP-1) and promotion of nutrient
absorption via expansion of themucosal epithelium (GLP-2) [24-
26]. However, increased secretion of both hormones is also seen
after intestinal injury induced by chemotherapy in mice and rats
[27-30] as well as in gut ischemia and inflammatory bowel dis-
ease in humans [31,32]. Importantly, GLP-2 and/or GLP-1 were
found to have a trophic effect on the small intestine in several
studies in rodents [33-37]. Additionally, GLP-2 has been shown
to stabilize the integrity of intestinal epithelial barrier [38-41],
and both GLP-1 and GLP-2 administration reduces chemother-
apy-induced intestinal injury [27,42-45].
Based on these studies we hypothesized that elevated lev-
els of GLP-1 could be an early marker of gut injury and poten-
tially predict treatment-related complications in patients
undergoing high-dose chemotherapy. The present study repre-
sents the first investigation of fasting GLP-1 plasma levels at
consecutive time points in patients treated with high-dose
chemotherapy followed by ASCT. Our findings indicate that
increased levels of GLP-1 may serve as an early predictor of
systemic inflammation and infection in these patients.METHODS
Study Population
We prospectively included 66 patients (ages 20 to 72 years) undergoing
ASCT at University Hospital Rigshospitalet, Copenhagen, Denmark from Feb-
ruary 2015 to October 2016. Written and oral informed consent was obtained
for all included patients. The study was approved by the local ethics commit-
tee (H-7-2014-016) and conducted in accordance with the Declaration of Hel-
sinki. Inclusion criteria were patients scheduled for ASCT, age older than 18
years, and patient informed consent. Of 68 eligible patients, 2 were lost to fol-
low-up before 3 weeks after transplantation due to transfer to other hospitals
and therefore were excluded from the study.
The choice of pretransplant conditioning was based on the diagnosis in
accordance with international guidelines, with all patients with myelomas
receiving conditioning regimen 1 and all patients except 2 with lymphoma
receiving conditioning regimen 2 (Table 1). All patients received oral antimi-
crobial prophylaxis consisting of ciprofloxacin, coamoxiclav, and fluconazole
from day +4. Intravenous treatment with piperacillin/tazobactam or merope-
nem antibiotics was given based on daily measurements of body temperature
and was administered according to a standardized regimen during days with
fever (>38.5°C) until body temperature declined below 38.5°C. Body temper-
ature was measured daily.Inflammatory Parameters
CRP was monitored routinely in all patients every other day as a mini-
mum during the first 3 weeks post-transplantation, and extra measurements
were taken at the discretion of the physician in charge. When more than 1
measurement per day per patient was available, we calculated the mean to
represent the CRP level of that day. Post-transplantation CRPmax was defined
as the maximum CRP value from day +1 to day +21. CRP was analyzed using
Modular P Module (Roche, Basel, Switzerland) (upper normal limit, 10 mg/L)
at the Department of Clinical Biochemistry, University Hospital Rigshospita-
let. Blood cultures were routinely collected on all patients with fever before
initiation of i.v. antibiotic treatment, and results were registered from day
14 to day +30.Quantification of GLP-1
Blood samples were collected at 5 time points during ASCT: before initia-
tion of the conditioning regimen (baseline), at the day of transplantation
before stem cell infusion (day 0), and at days +7, +14, and +21 post-transplan-
tation. EDTA anticoagulated blood was centrifuged within 2 hours after col-
lection, and plasma was isolated and stored at ¡80°C until analysis.
The plasma concentration of GLP-1 was measured in duplicates using a
total GLP-1 ELISA (cat. no. 10-1278-01; Mercodia, Uppsala, Sweden) accord-
ing to the manufacturer's instructions. This ELISA measures both active GLP-1
(7-36) amide and the degraded isoform GLP-1 (9-36) amide and reflects the
secretion of GLP-1 because amidated isoforms of GLP-1 are highly predomi-
nant in humans [46]. Measurement range was .9 to 940 pmol/L.
Statistical Analyses
The associations of GLP-1 over time and with patient-specific characteris-
tics (conditioning regimen, age, sex) were analyzed with a mixed model with
a compound symmetry covariance matrix, and the significance was assessed
with a Wald test with the degrees of freedom calculated using the Sat-
terthwaite approximation. GLP-1 was log-transformed due to its skewness.
Similarly, when investigating the association between CRP over time and
dichotomized GLP-1 level at day 0. The Mann-Whitney Utest was used for
comparison of continuous variables between groups. Simple and adjusted lin-
ear regression models were used to determine the association between
GLP-1 day 0 (log 2-transformed) and CRP and negative binomial regression
models to determine the association with days with fever. In subanalyses
where conditioning was included as a covariate, only the 63 patients in either
group 1 (high-dose melphalan, with or without bortezomib or carfilzomib) or
group 2 (cytarabine in combination with carmustine, etoposide, and melpha-
lan) were included.
A 2-sided P < .05 was considered statistically significant. All statistical
analyses were performed using R statistical software version 2.15.3 (R Foun-
dation for Statistical Computing, Vienna, Austria) and RStudio (RStudio, Bos-
ton, MA).
RESULTS
Clinical characteristics of the included patients are listed in
Table 1.
GLP-1 Levels
The median GLP-1 level before conditioning for all included
patients was 7.7 pmol/L (interquartile range, 4.3 to 11.5), which
is within the range of the 95% confidence interval (CI) of fasting
levels of 774 healthy individuals (1 to 21 pmol/L) [47]. Overall,
the association between GLP-1 levels and measurement time
points was significant (P = .010), and GLP-1 levels increased sig-
nificantly from before conditioning to day 0 (33%; 95% CI,3 to
70; P = .027) and peaked at day +7 (41%; 95% CI, 10 to 81;
P = .0073) (Figure 1A).
Figure 1. GLP-1 levels during ASCT from before start of conditioning until 21 days post-transplant. Day 0 refers to the day of transplantation after conditioning with
high-dose chemotherapy. Horizontal line indicates median GLP-1. (A) All included patients. Statistical evaluation indicates GLP-1 levels compared with precondition-
ing levels (*P = .03; **P = .007). (B) Patients stratified by conditioning group. Patients conditioned with cytarabine in combination with carmustine, etoposide, and mel-
phalan (group 2) had generally higher GLP-1 levels than patients treated with high-dose melphalan with or without bortezomib or carfilzomib (group 1). Statistical
evaluation indicates differences between the 2 conditioning groups (***P < .001 [day 0]; P = .048 [day +7]; P = .03 [day +21]).
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(P = .38), age (P = .11), or diagnosis (P = .061). GLP-1 was signifi-
cantly associated with conditioning group (P< .0001) with lev-
els at days 0, +7, and +21 significantly higher in conditioning
group 2 (patients with lymphoma) than in group 1 (patients
with multiple myeloma) (155% [95% CI, 78 to 465; P < .0001],
44% [95% CI, .3 to 108; P = .048], and 54% [95% CI, 2 to 131;
P = .03], respectively) (Figure 1B). Moreover, overall GLP-1 was
significantly lower for older patients (11% per 10 years; 95% CI,
3 to 18; P = .013) but was not associated with sex (P = .35).Inflammatory Response
Of the 48 patients with CRP measured at day 0, 44 (92%)
had CRP day 0 within normal range (10 mg/L). Post-trans-
plantation median CRP increased and reached a peak at day +9
after transplantation (Figure 2A), with daily median levels
from day +2 and onward significantly higher than CRP day 0
(all P < .0017). Median post-transplant CRPmax was 181 mg/L
(interquartile range, 61 to 266).
Fifty-two patients (79%) experienced fever > 38.5°C during
the first 3 weeks post-transplant. The median duration of fever
was 8 days (interquartile range, 3 to 12). At day +11 the highest
number of patients experiencing fever was seen (47 [71%])
(Figure 2B).Figure 2. CRP and fever during treatment. CRP levels (A) and frequency of patients wit
indicates median CRP level.GLP-1 and Inflammation
We investigated associations between GLP-1 and CRP and
fever. A doubling in GLP-1 at day 0 was associated with an
increase of 46 mg/L in CRPmax (95% CI, 24 to 68; P = .00018)
(Figure 3A) and an increase of 32% in days with fever (95% CI, 8
to 62; P = .0058) (Figure 3B). When adjusting for conditioning
group the associations with GLP-1 at day 0 remained signifi-
cant (P = .024 and P = .042, respectively). In simple regression
analyses, conditioning group 2 had on average 80 mg/L higher
CRPmax compared with group 1 (95% CI, 22 to 138; P = .0091)
and almost twice as many days with fever (96%; 95% CI, 27 to
201; P = .022). By comparing CRP in 2 groups stratified by the
median values of GLP-1 at day 0 (9 pmol/L), we could demon-
strate higher levels of CRP from days +3 to +10 in those with
high GLP-1 values on day 0 (all P  .041) (Figure 4).
Infections
Only 2 patients presented with a positive blood culture
(both post-transplant), which did not allow investigation of
association between documented infections and GLP-1 levels.
Survival
Nine patients (14%) died during 1 year of follow-up, and 2
of these died because of treatment-related complications.
These limited numbers did not allow conclusions regarding
prediction of survival by GLP-1 measurements.h fever (B) after high-dose chemotherapy and stem cell infusion. Black line in A
Figure 3. GLP-1 day 0 associations with inflammation after transplantation. Associations between GLP-1 levels at day 0 and inflammatory response: CRPmax (A) and
days with fever (B) after ASCT. P values by simple linear regression and negative binomial regression analyses showed a significant association between GLP-1 levels
at day 0 and inflammatory response.
1088 M.S. Ebbesen et al. / Biol Blood Marrow Transplant 25 (2019) 10851091DISCUSSION
In this study we investigated fasting GLP-1 levels in the
early toxic phase in patients undergoing ASCT after high-dose
chemotherapy. Our data indicate that fasting levels of GLP-1
are increased after chemotherapy, peaking around day +7 after
the transplant, and, importantly, our data indicate that high
levels of GLP-1 shortly after the completion of high-dose che-
motherapy are predictive of subsequent increases in CRP dur-
ing the first 3 weeks after transplantation.
GLP-2 is a well-known growth factor for intestinal epithe-
lium, stimulating proliferation of crypt cells while inhibiting
apoptosis of enterocytes in the small intestine [26,33,34,
48-50]. A similar trophic effect of GLP-1 has been suggested by
studies on rats [35,51] and mice [36,52] showing small intesti-
nal and colonic growth after treatment with GLP-1 analogues.
Furthermore, endogenous GLP-1 contributes to intestinalFigure 4. CRP after transplantation by GLP-1 increase at day 0. Median CRP levels afte
Asterisk indicates statistical difference in CRP levels between the 2 groups (all P  .041epithelial recovery after chemotherapy in mice [27], whereas
loss of the GLP-1 receptor increases the severity of intestinal
injury [53].
GLP-1 may also act as an anti-inflammatory peptide attenu-
ating both local and systemic inflammation [54,55] by improv-
ing mucosal integrity through interactions with intestinal
intraepithelial lymphocytes, found to express functional GLP-1
receptors [53,56]. In addition, GLP-1 has stimulatory effects on
innate immune mechanisms, including production of alpha-
defensin by Paneth cells [57]. GLP-1 treatment has shown
anti-inflammatory effects by suppressing proinflammatory
cytokines such as tumor necrosis factor-a, IL-6, and IL-1b in
intestinal mucosa in mice with colitis [58-60] and in humans
with diabetes type 1 and 2 and psoriasis [61-63]. Based on
these findings, it may be hypothesized that increased level of
GLP-1 in response to chemotherapy represents a protectiver ASCT in 2 groups stratified according to the median levels of GLP-1 at day 0.
).
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and fasten recovery of epithelial integrity, thereby limiting
inflammation.
To our knowledge we are the first to explore fasting GLP-1
levels in human subjects after chemotherapy treatment. How-
ever, our findings are in line with findings by Kissow et al. and
others showing increased levels of both GLP-1 and GLP-2 after
chemotherapy in rats [27] and mice [28-30]. Other studies
found increased GLP-1 or GLP-2 levels after nonchemother-
apy-related gut injury in humans [31,32] and animals [31],
lending support to the notion that these hormones are
secreted in response to intestinal injury.
Further evidence of such a protective effect is found in stud-
ies by Hytting et al. [30] showing that ablation of L cells in che-
motherapy-treated mice leads to severe mucositis and
insufficient intestinal healing, whereas chemotherapy-treated
mice with normal function of L cells show compensatory
hyperproliferation of intestinal epithelial cells in association
with a marked increase in GLP-2 secretion. This is in line with
data from Kissow et al. [27] showing similar findings when
antagonizing the GLP-1 receptor selectively. Furthermore,
Hytting et al. showed that co-treatment with both GLP-1 and
GLP-2 analogues was more effective than a single GLP-1 ana-
logue for rebuilding intestinal epithelium and maintaining
body weight in mice.
The mechanism behind the increase in GLP-1 after gut
injury is not fully understood, but data from Lebrun et al. [31]
suggest that innate responses to bacterial lipopolysaccharide
(LPS) may play a role in the induction of GLP-1 secretion.
Accordingly, enteroendocrine L cells are stimulated by LPS
through interaction with Toll-like receptor 4 after gut injury,
leading to a rapidly increased secretion of GLP-1 [31]. Other
studies in experimental animals confirmed increased GLP-1
secretion in response to LPS [64,65], apparently mediated
through proinflammatory cytokines including IL-6 [64,66] and
tumor necrosis factor-a [31,64,67]. Likewise, in humans Lebrun
et al. [31] found GLP-1 secretion after LPS administration in
volunteers. These authors also reported increased GLP-1 levels
after induction of ischemia in the human intestine in vivo, sug-
gesting a close relationship between gut inflammation and
GLP-1 secretion in humans.
Breaks in the mucosa after chemotherapy have been found
to serve as portals of entry for microorganisms, leading not
only to bacteremia but also to penetration of pathogen-associ-
ated molecular patterns and endogenous danger-associated
molecular patterns, produced as a result of cell death [68-70].
The resulting inflammatory response has been found to be pre-
dictive of organ toxicity and transplant-related mortality in
allogeneic hematopoietic SCT [5,14-16,20,71,72], and several
studies confirm a relationship between chemotherapy-
induced mucosal barrier injury and systemic inflammation
[4,8,9,19,73]. Our finding of a positive association between CRP
and GLP-1 is in line with these results. Altogether, these stud-
ies suggest that increased levels of GLP-1 during chemotherapy
may be induced by LPS in combination with an initial release of
inflammatory cytokines.
Individuals with type 2 diabetes mellitus have a diminished
meal-related GLP-1 secretion [74], and we could speculate this
lower protection from GLP-1 after meals makes the intestinal
epithelium more vulnerable after chemotherapy, resulting in
higher risk of mucositis and severe systemic inflammation.
Furthermore, it is not known if a diminished meal-related GLP-
1 secretion makes the L cells less responsive to other secretory
stimuli as well, potentially making the diabetes diagnosis a
confounder for our results. Eight patients in our cohort werediagnosed with type 2 diabetes at the time of transplant, and
these patients did not differ from the rest of the study popula-
tion in GLP-1 levels or degree of systemic inflammation.
Nutrient ingestion is the primary physiologic stimulatory
signal for GLP-1 and GLP-2 secretion [25,75]. Previous studies
in rats [48] and mice [76] showed that fasting for 1 or a couple
of days resulted in atrophy of the small intestine but could be
reversed by refeeding and that this refeeding adaptation was
prevented upon antagonizing the GLP-2 receptor. Other stud-
ies found that intestinal atrophy seen in rodents and pigs after
total parenteral nutrition [48,77] could be ameliorated by co-
infusion of GLP-2 [41,77,78]. Because patients undergoing
high-dose chemotherapy treatment often have low or no
enteral nutrition for days during the first few weeks after
transplantation, the direct toxic effects of chemotherapy could
be aggravated through insufficient GLP-1 and GLP-2 secretion,
leading to incomplete healing and regeneration of the intesti-
nal epithelium. Accordingly, further studies should focus on
the role of enteral feeding in maintaining gut integrity through
induction of GLP-1 and GLP-2. The variation in GLP-1 levels
seen both pre- and post-transplant, even after stratification
into conditioning regimens, demonstrates that additional fac-
tors may influence fasting plasma GLP-1 levels in humans,
indicating a need for further studies to fully understand the
potential of GLP-1 as a prognostic marker in clinical settings.
In conclusion, our data indicate that high-dose chemother-
apy leads to increased fasting levels of GLP-1 and that these
are predictive of increased systemic inflammation, adding to
the mounting evidence that GLP-1 plays an important role in
regulation of the mucosal defense. GLP-1 should be further
investigated as a potential early predictive biomarker of treat-
ment-related morbidity.ACKNOWLEDGMENTS
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